These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 26895730)

  • 1. Investigation of receptor binding and functional characteristics of hemopressin(1-7).
    Dvorácskó S; Tömböly C; Berkecz R; Keresztes A
    Neuropeptides; 2016 Aug; 58():15-22. PubMed ID: 26895730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the cannabinoid 1 receptor peptide ligands hemopressin, (m)RVD-hemopressin(α) and (m)VD-hemopressin(α) on memory in novel object and object location recognition tasks in normal young and Aβ1-42-treated mice.
    Zhang RS; He Z; Jin WD; Wang R
    Neurobiol Learn Mem; 2016 Oct; 134 Pt B():264-74. PubMed ID: 27481221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and quantification of a new family of peptide endocannabinoids (Pepcans) showing negative allosteric modulation at CB1 receptors.
    Bauer M; Chicca A; Tamborrini M; Eisen D; Lerner R; Lutz B; Poetz O; Pluschke G; Gertsch J
    J Biol Chem; 2012 Oct; 287(44):36944-67. PubMed ID: 22952224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of pepcan-23 as pro-peptide of RVD-hemopressin (pepcan-12) and stability of hemopressins in mice.
    Glasmacher S; Gertsch J
    Adv Biol Regul; 2021 May; 80():100808. PubMed ID: 33799079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemopressin Peptides as Modulators of the Endocannabinoid System and their Potential Applications as Therapeutic Tools.
    Macedonio G; Stefanucci A; Maccallini C; Mirzaie S; Novellino E; Mollica A
    Protein Pept Lett; 2016; 23(12):1045-1051. PubMed ID: 27748182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further Characterization of Hemopressin Peptide Fragments in the Opioid and Cannabinoid Systems.
    Szlavicz E; Perera PS; Tomboly C; Helyes Z; Zador F; Benyhe S; Borsodi A; Bojnik E
    Anesth Analg; 2015 Dec; 121(6):1488-94. PubMed ID: 26465932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological characterization of rat VD-hemopressin(α), an α-hemoglobin-derived peptide exhibiting cannabinoid agonist-like effects in mice.
    Zheng T; Zhang T; Zhang R; Wang ZL; Han ZL; Li N; Li XH; Zhang MN; Xu B; Yang XL; Fang Q; Wang R
    Neuropeptides; 2017 Jun; 63():83-90. PubMed ID: 28010996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antinociceptive effects of central administration of the endogenous cannabinoid receptor type 1 agonist VDPVNFKLLSH-OH [(m)VD-hemopressin(α)], an N-terminally extended hemopressin peptide.
    Han ZL; Fang Q; Wang ZL; Li XH; Li N; Chang XM; Pan JX; Tang HZ; Wang R
    J Pharmacol Exp Ther; 2014 Feb; 348(2):316-23. PubMed ID: 24307201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anorexigenic effects induced by RVD-hemopressin(α) administration.
    Ferrante C; Recinella L; Leone S; Chiavaroli A; Di Nisio C; Martinotti S; Mollica A; Macedonio G; Stefanucci A; Dvorácskó S; Tömböly C; De Petrocellis L; Vacca M; Brunetti L; Orlando G
    Pharmacol Rep; 2017 Dec; 69(6):1402-1407. PubMed ID: 29145068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anxiogenic-like effects induced by hemopressin in rats.
    Fogaça MV; Sonego AB; Rioli V; Gozzo FC; Dale CS; Ferro ES; Guimarães FS
    Pharmacol Biochem Behav; 2015 Feb; 129():7-13. PubMed ID: 25462856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (m)RVD-hemopressin (α) and (m)VD-hemopressin (α) improve the memory-impairing effect of scopolamine in novel object and object location recognition tasks in mice.
    Zhang R; Lao K; Lu B; Guo H; Cheng J; Chen P; Gou X
    Peptides; 2021 Feb; 136():170442. PubMed ID: 33171279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pepcan-12 (RVD-hemopressin) is a CB2 receptor positive allosteric modulator constitutively secreted by adrenals and in liver upon tissue damage.
    Petrucci V; Chicca A; Glasmacher S; Paloczi J; Cao Z; Pacher P; Gertsch J
    Sci Rep; 2017 Aug; 7(1):9560. PubMed ID: 28842619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemopressin is an inverse agonist of CB1 cannabinoid receptors.
    Heimann AS; Gomes I; Dale CS; Pagano RL; Gupta A; de Souza LL; Luchessi AD; Castro LM; Giorgi R; Rioli V; Ferro ES; Devi LA
    Proc Natl Acad Sci U S A; 2007 Dec; 104(51):20588-93. PubMed ID: 18077343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent cannabinergic indole analogues as radioiodinatable brain imaging agents for the CB1 cannabinoid receptor.
    Deng H; Gifford AN; Zvonok AM; Cui G; Li X; Fan P; Deschamps JR; Flippen-Anderson JL; Gatley SJ; Makriyannis A
    J Med Chem; 2005 Oct; 48(20):6386-92. PubMed ID: 16190764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: evidence from postmortem human brain.
    Erdozain AM; Diez-Alarcia R; Meana JJ; Callado LF
    Biochem Pharmacol; 2012 Jan; 83(2):260-8. PubMed ID: 22093909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner.
    Zádor F; Lénárt N; Csibrány B; Sántha M; Molnár M; Tuka B; Samavati R; Klivényi P; Vécsei L; Marton A; Vizler C; Nagy GM; Borsodi A; Benyhe S; Páldy E
    Neuropharmacology; 2015 Feb; 89():298-307. PubMed ID: 25446673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding of the hemopressin peptide to the cannabinoid CB1 receptor: structural insights.
    Scrima M; Di Marino S; Grimaldi M; Mastrogiacomo A; Novellino E; Bifulco M; D'Ursi AM
    Biochemistry; 2010 Dec; 49(49):10449-57. PubMed ID: 21062041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemopressin as a breakthrough for the cannabinoid field.
    Heimann AS; Dale CS; Guimarães FS; Reis RAM; Navon A; Shmuelov MA; Rioli V; Gomes I; Devi LL; Ferro ES
    Neuropharmacology; 2021 Feb; 183():108406. PubMed ID: 33212113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Micromolar concentrations of rimonabant directly inhibits delta opioid receptor specific ligand binding and agonist-induced G-protein activity.
    Zádor F; Kocsis D; Borsodi A; Benyhe S
    Neurochem Int; 2014 Feb; 67():14-22. PubMed ID: 24508403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Signaling molecules targeting cannabinoid receptors: Hemopressin and related peptides.
    Wei F; Zhao L; Jing Y
    Neuropeptides; 2020 Feb; 79():101998. PubMed ID: 31831183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.